Zota Health Care Limited ZOTA NSEPHARMA
Healthcare · Biotechnology · India
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, health supplements, over-the-counter products, wellness and ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.
READ MORE ›₹1,125.20
+12.94% 1Y
Market & Price
Market Cap
₹3,413.03 Cr
Current Price
₹1,125.20
High / Low (52W)
₹1,687.00 / ₹925.81
Beta
0.47
Valuation
Stock P/E
-
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹103.04
Price to Book
10.92
P/S
6.34
EV/EBITDA
219.76
Dividend Yield
0.09%
Profitability & Returns
ROCE
-6.99%
ROE
-16.05%
ROA
-5.09%
Profit Margin
-13.73%
Op Margin
-11.22%
EPS (Latest Qtr)
₹-4.13
EPS (TTM)
₹-22.50
Balance Sheet & Liquidity
Debt/Equity
0.39
Quick Ratio
0.71
Current Ratio
1.93
Debt
₹270.44 Cr
Total Assets
₹1,131.05 Cr
Current Assets
₹457.17 Cr
Working Capital
₹219.89 Cr
Ownership
Promoter Holding
0.00%
Chg in Prom Hold
-
FII / Inst Holding
1.44%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹4,074.40 Cr
Total Revenue (TTM)
₹538.66 Cr
EBITDA
₹18.54 Cr
Free Cash Flow
₹-171.20 Cr
Operating Cash Flow
₹-84.43 Cr
Shares Outstanding
₹3.03 Cr
Gross Margin
60.28%
Payout Ratio
53.20%
Growth (CAGR)
Revenue 5Y
56.71%
Profit 5Y
-393.59%
Revenue (YoY)
67.70%
Earnings (YoY)
-
PROS
- Compounding revenue at 56.7% over 5 years.
CONS
- Earnings shrank at -393.6% CAGR over 5 years.
- Trading 33.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZOTA Zota Health Care Limited NSEPHARMA | 1,125.20 | - | ₹3,413.03 Cr | 0.09% | -6.99% | -16.05% | 56.71% | -393.59% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 67.28 Cr | 72.12 Cr | 97.27 Cr | 103.58 Cr | 142.95 Cr | 163.18 Cr |
| Cost of Revenue | 31.26 Cr | 31.83 Cr | 47.87 Cr | 45.13 Cr | 56.77 Cr | 59.62 Cr |
| Gross Profit | 36.02 Cr | 40.29 Cr | 49.40 Cr | 58.45 Cr | 86.18 Cr | 103.56 Cr |
| Operating Expenses | 46.40 Cr | 57.71 Cr | 61.25 Cr | 69.17 Cr | 108.87 Cr | 121.87 Cr |
| Operating Income | -10.38 Cr | -17.42 Cr | -11.85 Cr | -10.72 Cr | -22.70 Cr | -18.31 Cr |
| EBITDA | -32.74 L | -5.56 Cr | 3.47 Cr | 4.83 Cr | 1.28 Cr | 5.91 Cr |
| Interest Expense | 2.85 Cr | 1.57 Cr | 3.46 Cr | 3.24 Cr | 4.97 Cr | 5.32 Cr |
| Pretax Income | -12.69 Cr | -18.48 Cr | -14.30 Cr | -13.08 Cr | -25.95 Cr | -26.42 Cr |
| Tax Provision | -51.20 L | 46.14 L | -1.42 Cr | 69.31 L | 3.69 Cr | -11.96 Cr |
| Net Income | -12.10 Cr | -18.68 Cr | -12.89 Cr | -14.32 Cr | -29.50 Cr | -14.17 Cr |
| Diluted EPS | -4.57 | -6.80 | -4.57 | -4.92 | -9.44 | -4.13 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 139.96 Cr | 180.49 Cr | 292.97 Cr | 538.66 Cr |
| Cost of Revenue | - | 84.83 Cr | 100.15 Cr | 137.30 Cr | 213.97 Cr |
| Gross Profit | - | 55.13 Cr | 80.34 Cr | 155.67 Cr | 324.69 Cr |
| Operating Expenses | - | 58.95 Cr | 92.95 Cr | 204.60 Cr | 388.60 Cr |
| Operating Income | - | -3.83 Cr | -12.61 Cr | -48.93 Cr | -63.91 Cr |
| EBITDA | - | 9.75 Cr | 8.21 Cr | -3.66 Cr | 19.98 Cr |
| Interest Expense | - | 2.49 Cr | 4.20 Cr | 10.78 Cr | 17.36 Cr |
| Pretax Income | - | -4.69 Cr | -16.16 Cr | -57.64 Cr | -79.84 Cr |
| Tax Provision | - | 1.08 Cr | -1.82 Cr | -90.55 L | -5.76 Cr |
| Net Income | - | -5.77 Cr | -14.35 Cr | -56.40 Cr | -73.94 Cr |
| Diluted EPS | 3.58 | -2.29 | -5.59 | -20.68 | - |
Compounded Sales Growth
| 5 Years: | 56.71% |
| 1 Year: | 67.70% |
Compounded Profit Growth
| 5 Years: | -393.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +12.94% |
| 6 Months: | -33.23% |
| 3 Months: | -11.44% |
| 1 Month: | -14.26% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 158.11 Cr | 228.33 Cr | 439.14 Cr | 1,131.05 Cr |
| Current Assets | - | 84.17 Cr | 111.62 Cr | 184.16 Cr | 457.17 Cr |
| Cash & Equivalents | - | 9.19 L | 67.67 L | 2.13 Cr | 7.77 Cr |
| Inventory | - | 41.79 Cr | 53.77 Cr | 105.68 Cr | 192.64 Cr |
| Receivables | - | 27.83 Cr | 27.24 Cr | 40.50 Cr | 73.52 Cr |
| Total Liabilities | - | 77.76 Cr | 138.35 Cr | 211.99 Cr | 434.89 Cr |
| Current Liabilities | - | 40.52 Cr | 73.68 Cr | 100.61 Cr | 237.27 Cr |
| Long Term Debt | - | 0 | 0 | 4.99 Cr | 6.37 Cr |
| Total Debt | - | 45.12 Cr | 95.28 Cr | 139.60 Cr | 270.44 Cr |
| Total Equity | - | 80.36 Cr | 89.98 Cr | 223.68 Cr | 693.49 Cr |
| Shares Outstanding | 2.52 Cr | 2.52 Cr | 2.58 Cr | 2.86 Cr | - |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.01 Cr | -5.98 Cr | -49.96 Cr | -84.43 Cr |
| Investing Cash Flow | - | 14.70 Cr | -12.90 Cr | -92.19 Cr | -313.56 Cr |
| Financing Cash Flow | - | -13.88 Cr | 18.78 Cr | 144.76 Cr | 489.94 Cr |
| Capital Expenditure | - | -12.50 Cr | -16.71 Cr | -45.98 Cr | -112.93 Cr |
| Free Cash Flow | - | -14.51 Cr | -22.69 Cr | -95.94 Cr | -197.36 Cr |
| Net Change in Cash | - | -1.18 Cr | -11.07 L | 2.61 Cr | 91.95 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 39.4% | 44.5% | 53.1% | 60.3% |
| Operating Margin % | - | -2.7% | -7.0% | -16.7% | -11.9% |
| Net Margin % | - | -4.1% | -7.9% | -19.3% | -13.7% |
| ROE % | - | -7.2% | -15.9% | -25.2% | -10.7% |
| ROCE % | - | -3.3% | -8.2% | -14.5% | -7.2% |
Shareholding Pattern
Insiders
0.00%
Institutions
1.44%
Public Float
1.44%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZOTA
No recent headlines available.